A Phase 3 interventional study of Saizen® A and Saizen® B in Children Born With Serious Intra-uterine Growth Retardation, sponsored by Merck KGaA, Darmstadt, Germany. Completed. Per ClinicalTrials.gov, last updated 2013-09-18.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Study of safety of Saizen® in children born with serious intra-uterine growth retardation (IUGR) treated to final height. An open, phase III study involving 17 centers in France.
The study enrolled children who have completed 3 or 2 years of treatment and at least one year of post treatment observation in the Sponsor Studies GF 4001 (Safety and Efficacy of Saizen in the Treatment of Young Children Born with Severe IUGR) or GF 6283 (Effect of Intermittent versus Continuous Saizen Therapy in Young Children Born with Severe IUGR), respectively.
Detailed description: Serious IUGR is a syndrome characterized by low birth length and weight for gestational age (less than 10 percentile). The secretion of growth hormone in response to provocative stimuli (e.g. arginine, insulin) is normal in these children. Apart from low birth weight, children born with IUGR may have minor or major malformations.
A catch-up period with a supraphysiological growth velocity generally occurs during the first 6 to 24 months of life in 80 to 90 percent (%) of these children. This generally allows them to reach normal height. That means that conversely, approximately 10 to 20% of children do maintain a statural handicap. Puberty occurs at a normal age and the retardation in bone maturation present during the first years of life disappears very quickly. This leads to short adult stature in subjects who have not shown spontaneous catch-up during the first years of life. A safe and effective means of promoting growth without accelerating the timing or tempo of puberty would therefore be desirable.
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Saizen® A
Drug: Saizen® B
Other: Observation only
Continuous or intermittent treatment with recombinant human Growth Hormone (r-hGH) 0.067 milligram/kilogram/day (mg/kg/day) subcutaneously (sc).
Also known as: r-hGH, Somatropin
Observed until the first signs of puberty and then continuous treatment with r-hGH 0.067 mg/kg/day sc or observed without treatment.
Also known as: r-hGH, Somatropin
Subjects were only observed.
Final Height
Final height was defined as the height reached 1 year after height velocity (HV) was less than 2 centimeter/year (cm/year). Height velocity was the change in height since the previous year's measurement. Height was measured with a wall-mounted stadiometer (or in supine position if the participant's age was less than 3 years) and the measurement was repeated thrice by the same observer. The mean of the values obtained in the repeated measurements was taken for the analysis.
Time frame: One year after final height was attained up to 10.6 years
Height Standard Deviation Score (HSDS)
HSDS was calculated as height minus reference mean height divided by SD of the reference mean height, both given by the reference growth table (Sempe) for the corresponding chronological age at the height measurement. Greater HSDS indicate greater height. (Sempe M et al., 1979)
Time frame: One year after final height was attained up to 10.6 years
Parental Adjusted Height Standard Deviation Score (PAHSDS)
PAHSDS is the distance between the participant's current and target heights, expressed in units of SD of the height distribution of the reference population. Target height is a measure of the height which the participant could hypothetically reach based only on his parents' heights. Target height standard deviation score (THSDS) was calculated as target height minus mean adult height of the reference population divided by SD of the mean adult height of the reference population.
Time frame: One year after final height was attained up to 10.6 years
Participants who completed 3 or 2 years treatment and at least 1 year post treatment observation in Sponsor Studies GF 4001 (Safety and Efficacy of Saizen in the Treatment of Young Children Born with Severe IUGR) or GF 6283 (Effect of Intermittent versus Continuous Saizen Therapy in Young Children Born with Severe IUGR), respectively were enrolled.
| Milestone | Saizen® Continuous (A1) | Saizen® Intermittent (A2) | Observed, Not Randomized (B0) | Observed Then Randomized to Saizen® (B1) | Observed Then Randomized to Observation (B2) | Observation (C) |
|---|---|---|---|---|---|---|
| Started | 23 | 23 | 2 | 14 | 14 | 15 |
| Completed | 8 | 12 | 0 | 6 | 7 | 9 |
| Not completed | 15 | 11 | 2 | 8 | 7 | 6 |
| Withdrew: Lost to follow-up | 2 | 5 | 2 | 1 | 4 | 3 |
| Withdrew: Withdrawal by subject | 8 | 2 | 0 | 4 | 1 | 3 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Non-compliance | 0 | 1 | 0 | 1 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 4 | 2 | 0 | 2 | 1 | 0 |
Final height was defined as the height reached 1 year after height velocity (HV) was less than 2 centimeter/year (cm/year). Height velocity was the change in height since the previous year's measurement. Height was measured with a wall-mounted stadiometer (or in supine position if the participant's age was less than 3 years) and the measurement was repeated thrice by the same observer. The mean of the values obtained in the repeated measurements was taken for the analysis.
| cm | Non-Final Height: Not Treated | Non-Final Height: Treated | Final Height: Not Treated | Final Height: Treated |
|---|---|---|---|---|
| Final Height | 145.90 ± 16.08 | 150.06 ± 12.89 | 153.27 ± 8.71 | 155.59 ± 8.38 |
HSDS was calculated as height minus reference mean height divided by SD of the reference mean height, both given by the reference growth table (Sempe) for the corresponding chronological age at the height measurement. Greater HSDS indicate greater height. (Sempe M et al., 1979)
| standard deviation score | Non-Final Height: Not Treated | Non-Final Height: Treated | Final Height: Not Treated | Final Height: Treated |
|---|---|---|---|---|
| Height Standard Deviation Score (HSDS) | -1.45 ± 0.76 | -1.90 ± 1.73 | -2.33 ± 1.01 | -1.99 ± 0.88 |
PAHSDS is the distance between the participant's current and target heights, expressed in units of SD of the height distribution of the reference population. Target height is a measure of the height which the participant could hypothetically reach based only on his parents' heights. Target height standard deviation score (THSDS) was calculated as target height minus mean adult height of the reference population divided by SD of the mean adult height of the reference population.
| standard deviation score | Non-Final Height: Not Treated | Non-Final Height: Treated | Final Height: Not Treated | Final Height: Treated |
|---|---|---|---|---|
| Parental Adjusted Height Standard Deviation Score (PAHSDS) | -0.82 ± 0.59 | -1.52 ± 1.92 | -1.64 ± 1.61 | -1.24 ± 1.39 |
| years | Non-Final Height: Treated | Final Height: Treated |
|---|---|---|
| Duration of Treatment | 4.09 ± 2.92 | 4.51 ± 2.20 |
| years | Non-Final Height: Not Treated | Non-Final Height: Treated | Final Height: Not Treated | Final Height: Treated |
|---|---|---|---|---|
| Duration of Participation in the Study | 2.08 ± 2.27 | 5.29 ± 2.89 | 4.10 ± 2.87 | 7.02 ± 2.06 |
Collected over Baseline up to Day 30 after end of study. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Not Treated | — | 1/32 (3.1%) | 16/32 (50%) |
| Treated | — | 13/59 (22%) | 52/59 (88.1%) |
| Event | Not Treated | Treated |
|---|---|---|
| EpiphysiolysisMusculoskeletal and connective tissue disorders | 0/32 | 4/59 |
| Knee deformityMusculoskeletal and connective tissue disorders | 0/32 | 2/59 |
| KeratoconusEye disorders | 1/32 | 0/59 |
| Limb asymmetryMusculoskeletal and connective tissue disorders | 0/32 | 1/59 |
| Femur fractureInjury, poisoning and procedural complications | 0/32 | 1/59 |
| Foot fractureInjury, poisoning and procedural complications | 0/32 | 1/59 |
| Head injuryInjury, poisoning and procedural complications | 0/32 | 1/59 |
| Congenital jaw malformationCongenital, familial and genetic disorders | 0/32 | 1/59 |
| Hereditary haemorrhagic telangiectasiaCongenital, familial and genetic disorders | 0/32 | 1/59 |
| AppendicitisInfections and infestations | 0/32 | 1/59 |
| Event | Not Treated | Treated |
|---|---|---|
| HeadacheNervous system disorders | 1/32 | 10/59 |
| PharyngitisInfections and infestations | 5/32 | 9/59 |
| BronchitisInfections and infestations | 3/32 | 8/59 |
| GastroenteritisInfections and infestations | 3/32 | 7/59 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 0/32 | 7/59 |
| NasopharyngitisInfections and infestations | 0/32 | 6/59 |
| InfluenzaInfections and infestations | 0/32 | 6/59 |
| AcneSkin and subcutaneous tissue disorders | 1/32 | 6/59 |
| Ear infectionInfections and infestations | 2/32 | 4/59 |
| RhinitisInfections and infestations | 1/32 | 4/59 |
| Age Continuous(years) | Non-Final Height: Not Treated | Non-Final Height: Treated | Final Height: Not Treated | Final Height: Treated | Total |
|---|---|---|---|---|---|
| Mean | 10.6 ± 3.0 | 9.2 ± 2.4 | 12.5 ± 3.1 | 9.5 ± 2.6 | 10.3 ± 3.0 |
| Sex: Female, Male(Participants) | Non-Final Height: Not Treated | Non-Final Height: Treated | Final Height: Not Treated | Final Height: Treated | Total |
|---|---|---|---|---|---|
| Female | 5 | 5 | 10 | 21 | 41 |
| Male | 5 | 8 | 12 | 25 | 50 |
| Race/Ethnicity, Customized(participants) | Non-Final Height: Not Treated | Non-Final Height: Treated | Final Height: Not Treated | Final Height: Treated | Total |
|---|---|---|---|---|---|
| Asian | 2 | 0 | 0 | 0 | 2 |
| Black | 0 | 0 | 0 | 1 | 1 |
| White | 8 | 13 | 22 | 45 | 88 |
| Original Study(participants) | Non-Final Height: Not Treated | Non-Final Height: Treated | Final Height: Not Treated | Final Height: Treated | Total |
|---|---|---|---|---|---|
| GF4001 | 6 | 6 | 18 | 22 | 52 |
| GF6283 | 4 | 7 | 4 | 24 | 39 |
| Birth Height(cm) | Non-Final Height: Not Treated | Non-Final Height: Treated | Final Height: Not Treated | Final Height: Treated | Total |
|---|---|---|---|---|---|
| Mean | 41.8 ± 4.3 | 42.2 ± 3.5 | 44.8 ± 3.4 | 42.3 ± 3.5 | 42.8 ± 3.7 |
| Birth Weight(g) | Non-Final Height: Not Treated | Non-Final Height: Treated | Final Height: Not Treated | Final Height: Treated | Total |
|---|---|---|---|---|---|
| Mean | 1848 ± 601.2 | 2076.9 ± 520.9 | 2312 ± 451.1 | 2030.9 ± 573.4 | 2085.3 ± 551.8 |
| Length of Gestation(weeks) | Non-Final Height: Not Treated | Non-Final Height: Treated | Final Height: Not Treated | Final Height: Treated | Total |
|---|---|---|---|---|---|
| Mean | 37 ± 2.9 | 37.3 ± 2.6 | 38.9 ± 1.5 | 37.9 ± 2.8 | 37.9 ± 2.6 |
No study locations are listed for this record.
The record gives a start of Nov 1998, a primary completion of Feb 2010 and a completion of Feb 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 2 years 7 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone
Merck KGaA, Darmstadt, Germany →